CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biowa who wrote (445)	12/7/1999 12:43:00 AM
From: Vector1	Read Replies (1) of 666

Biowa, I think the battle in first line treatment will be CHOP plus Rit v. Fludarabine plus Bex. Zev will not compete in front line treatment as DNA/IDPH will not want to canabalize existing sales of Rit. To my knowledge there are no studies going on which combine Zev and a chemo agent. IDPH dropped over 10% today. IF the complete response rate for Zev in Rit naive patients who have failed chemo twice is less than 25% we could see another decline tonight. However, we should not forget that unlike CLTR IDPH is not a one drug company. IDPH has a fairly deep pipeline and I think Rit will continue to be a major money maker for years to come. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next